Hartaj Singh
Stock Analyst at Oppenheimer
(1.46)
# 3,198
Out of 4,829 analysts
98
Total ratings
38.78%
Success rate
-11.71%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $184 → $123 | $36.27 | +239.12% | 10 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $96.91 | +28.99% | 15 | Apr 25, 2025 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $4.23 | +561.94% | 6 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,150 → $1,000 | $527.78 | +89.47% | 12 | Nov 6, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $301.42 | +99.06% | 7 | Oct 31, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $550 → $540 | $424.99 | +27.06% | 16 | Oct 30, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $24.25 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $1.58 | +532.91% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.63 | +3,580.98% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.93 | +366.32% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.80 | +2,122.22% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $8.38 | +162.53% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.41 | +369.21% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.56 | +41,566.67% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $23.96 | +25.21% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $184 → $123
Current: $36.27
Upside: +239.12%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $96.91
Upside: +28.99%
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $4.23
Upside: +561.94%
Regeneron Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $1,150 → $1,000
Current: $527.78
Upside: +89.47%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $301.42
Upside: +99.06%
Vertex Pharmaceuticals
Oct 30, 2024
Maintains: Outperform
Price Target: $550 → $540
Current: $424.99
Upside: +27.06%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $24.25
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $1.58
Upside: +532.91%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.63
Upside: +3,580.98%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.93
Upside: +366.32%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.80
Upside: +2,122.22%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $8.38
Upside: +162.53%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.41
Upside: +369.21%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.56
Upside: +41,566.67%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $23.96
Upside: +25.21%